Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Mar;35(3):284–289.

The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.

S A Eckernäs 1, B E Roos 1, P Kvidal 1, L O Eriksson 1, G A Block 1, R P Neafus 1, J R Haigh 1
PMCID: PMC1381576  PMID: 8471404

Abstract

1. It has been suggested that HMG CoA reductase inhibitors which are administered as inactive, lipophilic lactones (e.g. simvastatin) have a greater propensity to evoke nocturnal sleep disturbances than pravastatin, an inhibitor given in the active, hydrophilic, open-acid form. 2. The effects of 4 weeks treatment with equipotent doses of simvastatin (20 mg day-1) and pravastatin (40 mg day-1) have been compared using polysomnography and subjective sleep assessments in a double-blind, placebo-controlled, two-period, incomplete block design study involving 24 male patients with primary moderate hypercholesterolaemia (mean LDL cholesterol 5.11 mmol l-1). 3. Analysis of sleep EEG measures relevant to insomnia provided no evidence of significant differences between pravastatin, simvastatin and placebo, except in terms of entries and latency to stage I sleep. The number of entries to stage I sleep was significantly greater after simvastatin treatment than after either pravastatin or placebo (P < 0.05), but by contrast the latency to stage I sleep was significantly prolonged only in the pravastatin group (P < 0.05 vs placebo). 4. Subjective ratings of sleep initiation, maintenance and quality made during and after therapy were not significantly different between the three treatment groups. 5. It appears that the inherent hydrophobicity of simvastatin does not increase the occurrence of sleep disturbances in this patient population at a dose shown to elicit a characteristic hypolipidaemic response.

Full text

PDF
284

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barth J. D., Kruisbrink O. A., Van Dijk A. L. Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia. BMJ. 1990 Sep 29;301(6753):669–669. doi: 10.1136/bmj.301.6753.669-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Black D. M., Lamkin G., Olivera E. H., Laskarzewski P. M., Stein E. A. Sleep disturbance and HMG CoA reductase inhibitors. JAMA. 1990 Sep 5;264(9):1105–1105. doi: 10.1001/jama.1990.03450090041020. [DOI] [PubMed] [Google Scholar]
  3. Botti R. E., Triscari J., Pan H. Y., Zayat J. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol. 1991 Jun;14(3):256–261. doi: 10.1097/00002826-199106000-00010. [DOI] [PubMed] [Google Scholar]
  4. Bradford R. H., Shear C. L., Chremos A. N., Dujovne C., Downton M., Franklin F. A., Gould A. L., Hesney M., Higgins J., Hurley D. P. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991 Jan;151(1):43–49. doi: 10.1001/archinte.151.1.43. [DOI] [PubMed] [Google Scholar]
  5. Brown M. S., Goldstein J. L. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986 Apr 4;232(4746):34–47. doi: 10.1126/science.3513311. [DOI] [PubMed] [Google Scholar]
  6. Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499–502. [PubMed] [Google Scholar]
  7. Grundy S. M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988 Jul 7;319(1):24–33. doi: 10.1056/NEJM198807073190105. [DOI] [PubMed] [Google Scholar]
  8. HMG-CoA reductase inhibitors for hypercholesterolemia. N Engl J Med. 1988 Nov 3;319(18):1222–1223. doi: 10.1056/NEJM198811033191811. [DOI] [PubMed] [Google Scholar]
  9. Jenkins C. D., Stanton B. A., Niemcryk S. J., Rose R. M. A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol. 1988;41(4):313–321. doi: 10.1016/0895-4356(88)90138-2. [DOI] [PubMed] [Google Scholar]
  10. Koga T., Shimada Y., Kuroda M., Tsujita Y., Hasegawa K., Yamazaki M. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta. 1990 Jul 16;1045(2):115–120. doi: 10.1016/0005-2760(90)90139-o. [DOI] [PubMed] [Google Scholar]
  11. Pentikainen P. J., Saraheimo M., Schwartz J. I., Amin R. D., Schwartz M. S., Brunner-Ferber F., Rogers J. D. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol. 1992 Feb;32(2):136–140. doi: 10.1002/j.1552-4604.1992.tb03818.x. [DOI] [PubMed] [Google Scholar]
  12. Pietro D. A., Alexander S., Mantell G., Staggers J. E., Cook T. J. Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II). Am J Cardiol. 1989 Mar 15;63(11):682–686. doi: 10.1016/0002-9149(89)90251-8. [DOI] [PubMed] [Google Scholar]
  13. Pravastatin and simvastatin for hypercholesterolemia. Med Lett Drugs Ther. 1991 Mar 8;33(839):18–20. [PubMed] [Google Scholar]
  14. Raasch R. H. Pravastatin sodium, a new HMG-CoA reductase inhibitor. DICP. 1991 Apr;25(4):388–394. doi: 10.1177/106002809102500410. [DOI] [PubMed] [Google Scholar]
  15. Saito Y., Goto Y., Nakaya N., Hata Y., Homma Y., Naito C., Hayashi H., Ito H., Yamamoto M., Takeuchi I. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test. Atherosclerosis. 1988 Aug;72(2-3):205–211. doi: 10.1016/0021-9150(88)90082-2. [DOI] [PubMed] [Google Scholar]
  16. Spielberg S. P., Tobert J. A. HMG-CoA reductase inhibitors and sleep. Clin Pharmacol Ther. 1992 Jul;52(1):109–111. doi: 10.1038/clpt.1992.115. [DOI] [PubMed] [Google Scholar]
  17. Stein E., Kreisberg R., Miller V., Mantell G., Washington L., Shapiro D. R. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I. Arch Intern Med. 1990 Feb;150(2):341–345. [PubMed] [Google Scholar]
  18. Vgontzas A. N., Kales A., Bixler E. O., Manfredi R. L., Tyson K. L. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther. 1991 Dec;50(6):730–737. doi: 10.1038/clpt.1991.213. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES